

Nicola Valeri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4993799/publications.pdf>

Version: 2024-02-01

87
papers

6,565
citations

109321

35
h-index

66911

78
g-index

90
all docs

90
docs citations

90
times ranked

11523
citing authors

#	ARTICLE	IF	CITATIONS
1	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. <i>Frontiers in Endocrinology</i> , 2022, 13, 834075.	3.5	5
2	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021, 70, 1632-1641.	12.1	24
3	MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. <i>Cancer Discovery</i> , 2021, 11, 1228-1247.	9.4	45
4	Vault RNAs: hidden gems in RNA and protein regulation. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1487-1499.	5.4	26
5	Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2964-2966.	7.0	0
6	Challenges and perspectives for immunotherapy in Aesophageal cancer: A look to the future (Review). <i>International Journal of Molecular Medicine</i> , 2021, 47, .	4.0	3
7	Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 515-516.	8.1	1
8	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. <i>Cell Death and Differentiation</i> , 2021, 28, 2970-2982.	11.2	13
9	A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1197-1206.	4.4	2
10	Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. <i>Nature Communications</i> , 2021, 12, 366.	12.8	138
11	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. <i>Genes</i> , 2021, 12, 33.	2.4	23
12	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. <i>Nature Communications</i> , 2021, 12, 6738.	12.8	10
13	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. <i>Cancer Imaging</i> , 2021, 21, 67.	2.8	4
14	Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. <i>Hepatology</i> , 2020, 72, 982-996.	7.3	30
15	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , 2020, 99, 105-112.	1.8	6
16	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020, 10, 1634.	2.8	2
17	MicroRNAs as mediators of drug resistance mechanisms. <i>Current Opinion in Pharmacology</i> , 2020, 54, 44-50.	3.5	19
18	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020, 12, 2452.	3.7	20

#	ARTICLE	IF	CITATIONS
19	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. <i>Gastrointestinal Disorders</i> , 2020, 2, 212-235.	0.8	7
20	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. <i>Pathology Research and Practice</i> , 2020, 216, 152907.	2.3	17
21	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020, 25, 481-487.	3.7	77
22	Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. <i>Nature Communications</i> , 2020, 11, 1923.	12.8	79
23	MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. <i>Targeted Oncology</i> , 2020, 15, 261-278.	3.6	183
24	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients' Prognosis. <i>International Journal of Surgical Pathology</i> , 2019, 27, 816-835.	0.8	8
25	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 153-163.	4.4	49
26	A MYC-GCN2-eIF2 γ negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. <i>Nature Cell Biology</i> , 2019, 21, 1413-1424.	10.3	65
27	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	1.6	293
28	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. <i>British Journal of Cancer</i> , 2019, 121, 257-263.	6.4	53
29	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. <i>Epigenomics</i> , 2019, 11, 587-604.	2.1	29
30	Streamlining Detection of Fusion Genes in Colorectal Cancer: Having Faith in Precision Oncology in the (Tissue) Agnostic Era. <i>Cancer Research</i> , 2019, 79, 1041-1043.	0.9	15
31	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3830-3838.	7.0	42
32	Class(y) Dissection of <i>BRAF</i> Heterogeneity: Beyond Non-V600. <i>Clinical Cancer Research</i> , 2019, 25, 6896-6898.	7.0	7
33	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1479-1482.	1.0	10
34	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. <i>Translational Oncology</i> , 2019, 12, 282-291.	3.7	14
35	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. <i>Oncogene</i> , 2019, 38, 1717-1733.	5.9	29
36	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. <i>Clinical Colorectal Cancer</i> , 2019, 18, 64-71.e1.	2.3	10

#	ARTICLE	IF	CITATIONS
37	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018, 359, 920-926.	12.6	1,199
38	Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer trial. <i>Histopathology</i> , 2018, 72, 1180-1188.	2.9	31
39	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. <i>Scientific Reports</i> , 2018, 8, 1445.	3.3	55
40	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. <i>Gastroenterology</i> , 2018, 154, 1066-1079.e5.	1.3	94
41	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. <i>Gut</i> , 2018, 67, 1484-1492.	12.1	59
42	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 159-171.	2.0	10
43	LONG-NONCODING RNAs in gastroesophageal cancers. <i>Non-coding RNA Research</i> , 2018, 3, 195-212.	4.6	39
44	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. <i>Cancer Cell International</i> , 2018, 18, 131.	4.1	7
45	Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4151-4162.	5.4	150
46	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018, 8, 1270-1285.	9.4	187
47	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 280-284.	2.3	33
48	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, 2049-2058.	3.5	13
49	Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 226.	2.8	56
50	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. <i>Targeted Oncology</i> , 2018, 13, 423-436.	3.6	5
51	Translational research and application of basic biology to clinical trial development in GI cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 164-164.	1.7	6
52	The molecular landscape of colitis-associated carcinogenesis. <i>Digestive and Liver Disease</i> , 2017, 49, 326-330.	0.9	34
53	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. <i>Gut</i> , 2017, 66, 1268-1277.	12.1	75
54	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. <i>JAMA Oncology</i> , 2017, 3, 1197.	7.1	398

#	ARTICLE	IF	CITATIONS
55	Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. <i>American Journal of Clinical Pathology</i> , 2017, 147, 301-308.	0.7	23
56	Characterisation of the immune-related transcriptome in resected biliary tract cancers. <i>European Journal of Cancer</i> , 2017, 86, 158-165.	2.8	47
57	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 7543-7549.	7.0	12
58	Combining Molecularly Targeted Agents: Is More Always Better?. <i>Clinical Cancer Research</i> , 2017, 23, 1123-1125.	7.0	6
59	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 394.	1.6	72
60	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. <i>Oncotarget</i> , 2017, 8, 111795-111806.	1.8	6
61	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016, 37, 852-857.	2.8	15
62	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 115, 1343-1350.	6.4	27
63	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2721-2727.	1.6	214
64	Let-7c down-regulation in <i>Helicobacter pylori</i> -related gastric carcinogenesis. <i>Oncotarget</i> , 2016, 7, 4915-4924.	1.8	26
65	From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. <i>Histology and Histopathology</i> , 2016, 31, 25-32.	0.7	13
66	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , 2015, 26, 1936-1941.	1.2	24
67	An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. <i>International Journal of Cancer</i> , 2015, 137, 428-438.	5.1	119
68	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. <i>Oncotarget</i> , 2014, 5, 7162-7171.	1.8	35
69	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. <i>Cancer Cell</i> , 2014, 25, 469-483.	16.8	267
70	c-Src drives intestinal regeneration and transformation. <i>EMBO Journal</i> , 2014, 33, 1474-91.	7.8	56
71	An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. <i>Cancer Epidemiology</i> , 2014, 38, 583-590.	1.9	26
72	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. <i>Modern Pathology</i> , 2012, 25, 1333-1344.	5.5	48

#	ARTICLE	IF	CITATIONS
73	rs4919510 in hsa-mir-608 Is Associated with Outcome but Not Risk of Colorectal Cancer. PLoS ONE, 2012, 7, e36306.	2.5	85
74	Anti-miR-135b in colon cancer treatment: Results from a preclinical study.. Journal of Clinical Oncology, 2012, 30, 457-457.	1.6	2
75	MicroRNAs in the Pathogenesis of Cancer. Seminars in Oncology, 2011, 38, 724-733.	2.2	181
76	Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 786-791.	7.1	207
77	Nutlin-3 Downregulates the Expression of the Oncogene <i>TCL1</i> in Primary B Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2011, 17, 5649-5655.	7.0	17
78	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	7.4	256
79	Abstract 1178: Involvement of MEG3, a long non-coding RNA, in hepatocellular cancer (HCC). , 2011, , .		0
80	Comprehensive miRNA profiling of surgically staged endometrial cancer. American Journal of Obstetrics and Gynecology, 2010, 202, 656.e1-656.e8.	1.3	77
81	MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21098-21103.	7.1	333
82	Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes. Clinical Cancer Research, 2010, 16, 957-966.	7.0	108
83	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	7.1	306
84	Abstract 4086: Ultraconserved non-coding RNAs are involved in human hepatocellular cancer growth. , 2010, , .		0
85	MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis, 2009, 30, 912-917.	2.8	31
86	Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mammalian Genome, 2009, 20, 573-80.	2.2	91
87	Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics and Proteomics, 2009, 6, 195-204.	2.0	22